NASDAQ:ARTL Artelo Biosciences (ARTL) Stock Price, News & Analysis $1.35 -0.10 (-6.97%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$1.37 +0.02 (+1.26%) As of 11/20/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsSEC Filings About Artelo Biosciences Stock (NASDAQ:ARTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artelo Biosciences alerts:Sign Up Key Stats Today's Range$1.30▼$1.4950-Day Range$1.35▼$7.3152-Week Range$1.30▼$179.19Volume51,946 shsAverage Volume43,243 shsMarket Capitalization$1.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company developing treatments that target the endocannabinoid system and related biological pathways. Its research focuses on potential therapies for conditions with significant unmet medical needs, including cancer-related symptoms and pain. The company’s programs have included ART27.13, a cannabinoid receptor agonist being studied for cancer-related anorexia and cachexia, and ART26.12, a small-molecule inhibitor of fatty acid binding protein 5 under investigation for potential therapeutic applications. Artelo has also developed ART12.11, a cannabidiol-based cocrystal formulation. Artelo is headquartered in the San Diego area of California. Its work is centered on drug research and development rather than the commercial sale of approved medicines.AI Generated. May Contain Errors. Read More Artelo Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreARTL MarketRank™: 0.400645523435 of 5 starsArtelo Biosciences scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingArtelo Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Artelo Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtelo Biosciences has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.23% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently decreased by 20.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.20% of the stock of Artelo Biosciences is held by insiders.Percentage Held by Institutions0.87% of the stock of Artelo Biosciences is held by institutions.Read more about Artelo Biosciences' insider trading history. Receive ARTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTL Stock News HeadlinesArtelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial ResultsNovember 12, 2026 | markets.businessinsider.comArtelo Biosciences consensus price target increased 2,600% to $826.20November 2, 2026 | msn.comPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 22 at 1:00 AM | Base Camp Trading (Ad)Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on PainOctober 29, 2026 | globenewswire.comArtelo Biosciences to Present ART26.12 Data at IASP World Congress on Pain as First Selective FABP5 Inhibitor Advances Toward MAD StudyOctober 26, 2026 | quiverquant.comQArtelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on PainOctober 26, 2026 | globenewswire.comArtelo Biosciences To Feature First Clinical Results For ART26.12 At BIO-EuropeOctober 7, 2026 | rttnews.comArtelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor PlatformOctober 7, 2026 | globenewswire.comSee More Headlines ARTL Stock Analysis - Frequently Asked Questions How have ARTL shares performed this year? Artelo Biosciences' stock was trading at $32.94 at the beginning of the year. Since then, ARTL stock has decreased by 95.9% and is now trading at $1.3490. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences, Inc. (NASDAQ:ARTL) released its earnings results on Thursday, November, 12th. The company reported ($3.19) earnings per share for the quarter, topping analysts' consensus estimates of ($7.02) by $3.83. When did Artelo Biosciences' stock split? Artelo Biosciences's stock reverse split on the morning of Tuesday, March 10th 2026.The 1-3 reverse split was announced on Friday, March 6th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 9th 2026. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. When did Artelo Biosciences IPO? Artelo Biosciences (ARTL) raised $80,000 in an initial public offering on Friday, June 21st 2019. The company issued 8,000,000 shares at a price of $0.01 per share. How do I buy shares of Artelo Biosciences? Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include NIO (NIO), Ford Motor (F), FuelCell Energy (FCEL), Hepion Pharmaceuticals (HEPA), SNDL (SNDL), Tonix Pharmaceuticals (TNXP) and Tesla (TSLA). Company Calendar Last Earnings11/12/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ARTL's financial health is in the Red zone, according to TradeSmith. ARTL has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARTL CIK1621221 Webwww.artelobio.com Phone(858) 925-7049FaxN/AEmployees7Year Founded2017Profitability EPS (Trailing Twelve Months)($47.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-272.21% Return on Assets-159.13% Debt Debt-to-Equity RatioN/A Current Ratio10.47 Quick Ratio10.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.65 per share Price / Book0.20Miscellaneous Outstanding Shares937,000Free Float907,000Market Cap$1.26 million OptionableNot Optionable Beta0.01 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ARTL) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredThis Gold Pays Up To 15% (Government Can't Touch It)Larry Fink foresees $110 trillion in assets being tokenized, bigger than the entire US stock market. $1.6 bill...Decentralized Masters | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA New Independent “Federal Reserve” Has Just Emerged in AmericaA new independent Federal Reserve has reportedly been created for America. It could be publicly revealed as...Banyan Hill Publishing | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.